Parkinsons Disease News: Breaking Parkinsons Disease News, Comments and Articles. - Page: 3

Faulty energy production in brain cells leads to disorders ranging from Parkinson's to intellectual disability

Neuroscientists have shown for the first time that dysfunctional mitochondria in brain cells can lead to learning disabilities. The link between dysfunctional mitochondria and Parkinson's disease is known, but this new research shows that it is also...

Researchers Successfully Convert Human Skin Cells Into Embryonic Stem Cells

[WATCH VIDEO: Contracting Cardiomyocystes] redOrbit Staff & Wire Reports - Your Universe Online Researchers at Oregon Health & Science University (OSHU) and the Oregon National Primate Research Center (ONPRC) have successfully reprogrammed human skin cells to become embryonic stem cells capable of transforming into any other cell type in the body, a breakthrough that marks the first tim...

New York Mets And Project A.L.S. Step Up To The Plate For 11th Annual "A Night to Believe."

NEW YORK, May 16, 2013 /PRNewswire/ -- On June 7, 2013, The New York Mets and Project A.L.S. will team up for their 11th annual "A Night to Believe" event at Citi Field. This family event benefitting ALS research is proudly hosted by the Mets and will include a pre-party featuring unlimited food, drink and fun before guests move to exclusive seats to watch the Mets take on the Miami Marlins....

Human embryo stem cells cloning breakthrough

"Human embryonic stem cells created from adult tissue for first time," The Guardian reports, while the Daily Mail's front page leads with the somewhat fanciful warning that new research raises the "spectre of cloned babies". These headlines are based on newly published research into the use of a technique known as somatic cell nuclear transfer (SCNT) as part of embryonic stem c...

Are Texans Prepared To Pay For Long Term Care?

LTC Tree launched a new website that offers up-to-date statistics and news about the Texas Long Term Care Insurance industry. LTC Texas provides Texans with tools to help them plan for retirement and Long Term Care needs. Dallas, Texas (PRWEB) May 16, 2013 LTC Tree, a leader in the Long Term Care Insurance industry, launched a new website this week to help Texans plan for their Long Term Care nee...

Xeljanz, Nouriast priced and set for Japan launch

The latest reimbursement price listing in Japan will pave the way for the first launch anywhere of two drugs, Kyowa Hakko Kirin's Nouriast (istradefylline) for Parkinson's disease and Zeria's Acofide (acotiamide) for functional dyspepsia......

Neuro Kinetics in Tech Transfer Licensing Deal With Oregon Health & Science University

PITTSBURGH, PA -- (Marketwired) -- 05/16/13 -- Medical device manufacturer Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com) said today that it has licensed rights to patented diagnostic software developed at Oregon Health & Science University (OHSU) (www.ohsu.edu) that enables medical researchers to perform Pulse-Step-Sine Rotation tests to better understand vestibular system abnormalities...

Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion

– Nordion to Produce and Distribute Supplies of 123I-labeled Drug Product NAV5001 for Late-Phase Clinical Trials – Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has entered into an agreement with Nordion (Canada) Inc. to produce and supply...

Acadia raises $100 million in follow-on

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) raised $100 million through the sale of 8 million shares at $12.50 in a follow-on underwritten by Jefferies; Cowen; JMP Securities; Needham; Ladenburg Thalmann; Roth Capital Partners; and SunTrust Robinson Hu...

Stem cells recovered from cloned human embryos

Sense of Smell May Be a Vital Clue for Exercise Levels in Parkinson's Disease

Staten Island, NY (PRWEB) May 15, 2013 Most people with Parkinson’s Disease are unaware that they are losing their sense of smell. However, according to Dr. Ben Weinstock, a local physical therapist, a poor sense of smell could signal somethi...

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA are expected to be $100 million, before deducting underwriting discounts and commissions and other estimated...

Human skin cells converted into embryonic stem cells: First time human stem cells have been produced via nuclear transfer

Scientists have successfully reprogrammed human skin cells to become embryonic stem cells capable of transforming into any other cell type in the body. It is believed that stem cell therapies hold the promise of replacing cells damaged through injury...

Actor John O'Hurley Hosts New AAN Epilepsy Video

MINNEAPOLIS, May 15, 2013 /PRNewswire-USNewswire/ -- Television actor and "Dancing with the Stars" winner John O'Hurley is the host of Epilepsy: A Guide for Patients and Families, the latest free patient education DVD and guidebook produced by the American Academy of Neurology (AAN) and its foundation, the American Brain Foundation. This valuable resource answers important questions for peopl...

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView™ to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson’s disease. Kinesia ProView provides a standardized...

Kinesia ProView Launches to Visualize Parkinson's Symptom Response to Deep Brain Stimulation Programming

VALLEY VIEW, Ohio, May 15, 2013 /PRNewswire/ -- Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView™ [ http://www.glneurotech.com/kinesia/proview/index.php ] to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson's disease. Kinesia ProView provides a standardized platform to quantitatively assess...

First Ever Congressional Caucus on Tourette Syndrome Established

BAYSIDE, N.Y., May 15, 2013 /PRNewswire-USNewswire/ -- To kick off Tourette Syndrome Awareness Month (May 15-June 15), the national Tourette Syndrome Association (TSA) is pleased to announce the establishment of a timely and unprecedented bi-partisan Congressional Caucus on Tourette Syndrome. This important collaboration will enable TSA to promote critical legislation that supports individuals and...

Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277

May 15, 2013 TORONTO - Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation of apomorphine, the only drug approved to treat the immobility ("off") symptoms of Parkinson's disease, has completed a white paper providing background clinical information on apomorphine. The paper identifies the...

Sense of Smell May Be a Vital Clue for Exercise Levels in Parkinson's Disease

Weinstock Physical Therapy, PC Develops “Parkinson’s Exercise Prescription,” a Paradigm Shift in Rehabilitation. Staten Island, NY (PRWEB) May 15, 2013 Most people with Parkinson’s Disease are unaware that they are losing their sense of smell. However, according to Dr. Ben Weinstock, a local physical therapist, a poor sense of smell could signal something much worse: a loss of nerve cells...

Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277

TORONTO, ONTARIO -- (Marketwired) -- 05/15/13 -- Cynapsus Therapeutics Inc. (TSX VENTURE: CTH), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation of apomorphine, the only drug approved to treat the immobility ("off") symptoms of Parkinson's disease, has completed a white paper providing background clinical information on apomorphine. The pa...

Cynapsus Therapeutics Inc.: Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277

TORONTO -- (Marketwired) -- 05/15/13 -- Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation of apomorphine, the only drug approved to treat the immobility (off) symptoms of Parkinson's disease, has completed a white paper providing background clinical information on apomorphine. The paper identifies the...

Pharmaceutical Research: Cellular Uptake Mechanism and Therapeutic Utility of a Novel Peptide in Targeted-Delivery of Proteins into Neuronal Cells

Type: Original PaperPurposeThe peptide-based delivery system constitutes a potent approach to overcome the limitations of drug delivery in vitro and in vivo. We recently proposed a novel peptide RDP, which enables brain-targeting delivery of proteins...

OHSU research team successfully converts human skin cells into embryonic stem cells

(Oregon Health & Science University) Scientists at Oregon Health & Science University have successfully reprogrammed human skin cells to become embryonic stem cells capable of transforming into any other cell type in the body. It is believed that ste...

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and Cowe...

Acadia planning follow-on

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) proposed a follow-on late Tuesday underwritten by Jefferies; Cowen; JMP Securities; and Needham. Acadia plans to submit an NDA to FDA for pimavanserin around the end of next year. The small molecule serotonin...